This program is intended for oncologists and other multidisciplinary care team members involved in the care of patients with melanoma.
This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations for immunotherapy (collectively PD-1–, CTLA-4–, and LAG-3–directed immunotherapy) and targeted therapies (BRAF/MEK inhibitors) in early-stage and advanced-stage melanoma.
Upon completion of this activity, participants should be able to:
Consider evidence-based research findings and guideline recommendations for the use of immunotherapy (PD-1–, CTLA-4–, and LAG-3–directed immunotherapy) along with targeted therapies in melanoma, including adjuvant therapy, neoadjuvant therapy, or combined immunotherapy and targeted therapy for unresectable, metastatic disease
Devise treatment plans that incorporate immunotherapy for appropriate patients with resectable and unresectable melanoma, including those with BRAF-mutant or BRAF wild-type disease
Manage immune-related adverse events related to the use of immunotherapy in patients with melanoma across the spectrum of disease
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Allison Betof Warner, MD, PhD
Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Allison Betof Warner, MD, PhD: consultant/advisor/speaker: Bristol-Myers Squibb, Immatics, Instil Bio, Iovance, Lyell Immunopharma, Novartis, Pfizer; researcher: Iovance.
Evan J. Lipson, MD
Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Evan Lipson, MD: consultant/advisor/speaker: Bristol-Myers Squibb, CareDx, Eisai, Genentech, Immunocore, InstillBio; researcher: Bristol-Myers Squibb, Merck, Sanofi/Regeneron.
Michael Postow, MD
Chief, Melanoma Service
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Michael Postow, MD: consultant/advisor/speaker: Bristol-Myers Squibb, Chugai, Eisai, Merck, Nektar, Novartis, Pfizer, Replimune; researcher: Bristol-Myers Squibb, Infinity, Merck, Novartis, RGenix.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 21, 2023, through June 20, 2024:
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.